H. Lundbeck Completes Randomisation for DEEp SEA Phase III Trial on Dravet Syndrome
H. Lundbeck completes randomisation in its DEEp SEA Phase III bexicaserin trial, advancing a first‑in‑class treatment for Dravet syndrome and strengthening its epilepsy portfolio.
2 minutes to read
